Marinus Pharmaceuticals (NASDAQ:MRNS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Tuesday morning, Benzinga reports. They currently have a $27.00 target price on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Oppenheimer reissued a market perform rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Cantor Fitzgerald restated an overweight rating and set a $28.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. StockNews.com lowered Marinus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 6th. Royal Bank of Canada restated a sector perform rating and set a $3.00 price objective (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. Finally, Robert W. Baird restated a neutral rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $16.07.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.38 on Tuesday. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. Marinus Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.26. The stock has a market capitalization of $75.80 million, a PE ratio of -0.52 and a beta of 0.91. The business has a fifty day moving average price of $8.37 and a two-hundred day moving average price of $8.36.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. During the same period last year, the firm posted ($0.76) EPS. As a group, equities analysts predict that Marinus Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Marinus Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock valued at $20,749,000 after buying an additional 31,233 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its position in shares of Marinus Pharmaceuticals by 69.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after purchasing an additional 103,935 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Marinus Pharmaceuticals by 6.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock valued at $23,381,000 after purchasing an additional 173,226 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Marinus Pharmaceuticals by 58.4% during the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after purchasing an additional 1,089,913 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at about $134,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.